ANAEROBE 2016
Banz Alice, Riou Brigitte, Lantz Aude, Foussadier Agnès, bioMérieux, Marcy L’Etoile, France
Introduction and Objective:
Clostridium difficile infection (CDI) is an inflammation of the large intestine due to an infection with a spore-forming bacteria, C. difficile, causing diarrhea. It is a healthcare-associated disease linked to the use of antibiotics. Infection with C. difficile species is common, serious, and costly. The presence of C. difficile toxin in fecal samples is the most reliable indicator of true CDI, but immunoassays for toxin testing are not suitable as stand-alone tests due to a lack of sensitivity. All guidelines strongly recommend a two-step assay algorithm based on the detection of bacteria followed by toxin detection. Since 2010, many laboratories are performing molecular assays for toxin gene detection and an increase in CDI incidence has been observed. Nevertheless, the presence of genes does not always correlate with the presence of functional toxins, leading to an inability to distinguish a disease state from colonization. An automated 1-step assay with high sensitivity for C. difficile toxins could strongly improve the accuracy of CDI diagnosis and reduce costs.The objective of this study was to evaluate a quantitative assay using the SimoaTM technology for simultaneous detection of toxins A and B of C. difficile in human fecal samples.
Related Posts
Neurology
Comparative Spatial Analyses of the Tumor Immune Landscape in Mouse Models of Glioblastoma Using the PhenoCode Discovery Mouse Neuro Panel and Customized Markers
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Development of a Spatial Metabolic Map of Immunotherapy Sensitive and Resistant Cutaneous Skin Carcinoma
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Spatial Immunometabolic Profiling of Non-Small Cell Lung Cancer Reveals Distinct Immune Exclusion Patterns and Functional Niches
Analytical validation of a multiplex immunofluorescence 7-Biomarker Immunoprint® assay on the Akoya PhenoImager HT platform for stage I/II Melanoma
Neurology
Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Clinical validation of the LucentAD p-Tau 217 as a lab developed test (LDT) for clinical use
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
Neurology
Discovering novel plasma biomarkers for ischemic stroke: Lipidomic and metabolomic analyses in an aged mouse model
Journal of Lipid Research | August 2, 2024 Becktel DA, Frye JB, Le EH, Whitman SA, Schnellmann RG, Morrison HW, Doyle KP. J Lipid Res. 2024 https://doi.org/10.1016/j.jlr.2024.100614 Abstract Ischemic stroke…